Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease

Kelly R. Bales, Tatyana Verina, David J. Cummins, Yansheng Du, Richard C. Dodel, Josep Saura, Cindy E. Fishman, Cynthia A. Delong, Pedro Piccardo, Valerie Petegnief, Bernardino Ghetti, Steven M. Paul

Research output: Contribution to journalArticle

379 Citations (Scopus)

Abstract

We quantified the amount of amyloid β-peptide (Aβ) immunoreactivity as well as amyloid deposits in a large cohort of transgenic mice overexpressing the V717F human amyloid precursor protein (APP(V717F+/-) TG mice) with no, one, or two mouse apolipoprotein E (Apoe) alleles at various ages. Remarkably, no amyloid deposits were found in any brain region of APP(V717F+/-) Apoe(-/-) TG mice as old as 22 mo of age, whereas age-matched APP(V717F+/-) Apoe(+/-) and Apoe(+/+) TG mice display abundant amyloid deposition. The amount of Aβ immunoreactivity in the hippocampus was also markedly reduced in an Apoe gene dose-dependent manner (Apoe(+/+) > Apoe(+/-) >> Apoe(-/-)), and no Aβ immunoreactivity was detected in the cerebral cortex of APP(V717F+/-) Apoe(-/-) TG mice at any of the time points examined. The absence of apolipoprotein E protein (apoE) dramatically reduced the amount of both Aβ1-40 and Aβ1-42 immunoreactive deposits as well as the resulting astrogliosis and microgliosis normally observed in APP(V717F) TG mice. ApoE immunoreactivity was detected in a subset of Aβ immunoreactive deposits and in virtually all thioflavine-S-fluorescent amyloid deposits. Because the absence of apoE alters neither the transcription or translation of the APP(V717F) transgene nor its processing to Aβ peptide(s), we postulate that apoE promotes both the deposition and fibrillization of Aβ, ultimately affecting clearance of protease-resistant Aβ/apoE aggregates. ApoE appears to play an essential role in amyloid deposition in brain, one of the neuropathological hallmarks of Alzheimer's disease.

Original languageEnglish
Pages (from-to)15233-15238
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume96
Issue number26
DOIs
StatePublished - Dec 21 1999

Fingerprint

Apolipoproteins E
Amyloid
Transgenic Mice
Alzheimer Disease
Amyloid Plaques
Proteins
Amyloid beta-Protein Precursor
Brain
Transgenes
Cerebral Cortex
Hippocampus

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. / Bales, Kelly R.; Verina, Tatyana; Cummins, David J.; Du, Yansheng; Dodel, Richard C.; Saura, Josep; Fishman, Cindy E.; Delong, Cynthia A.; Piccardo, Pedro; Petegnief, Valerie; Ghetti, Bernardino; Paul, Steven M.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 96, No. 26, 21.12.1999, p. 15233-15238.

Research output: Contribution to journalArticle

Bales, Kelly R. ; Verina, Tatyana ; Cummins, David J. ; Du, Yansheng ; Dodel, Richard C. ; Saura, Josep ; Fishman, Cindy E. ; Delong, Cynthia A. ; Piccardo, Pedro ; Petegnief, Valerie ; Ghetti, Bernardino ; Paul, Steven M. / Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. In: Proceedings of the National Academy of Sciences of the United States of America. 1999 ; Vol. 96, No. 26. pp. 15233-15238.
@article{5b2226234f824db782c08210e9150037,
title = "Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease",
abstract = "We quantified the amount of amyloid β-peptide (Aβ) immunoreactivity as well as amyloid deposits in a large cohort of transgenic mice overexpressing the V717F human amyloid precursor protein (APP(V717F+/-) TG mice) with no, one, or two mouse apolipoprotein E (Apoe) alleles at various ages. Remarkably, no amyloid deposits were found in any brain region of APP(V717F+/-) Apoe(-/-) TG mice as old as 22 mo of age, whereas age-matched APP(V717F+/-) Apoe(+/-) and Apoe(+/+) TG mice display abundant amyloid deposition. The amount of Aβ immunoreactivity in the hippocampus was also markedly reduced in an Apoe gene dose-dependent manner (Apoe(+/+) > Apoe(+/-) >> Apoe(-/-)), and no Aβ immunoreactivity was detected in the cerebral cortex of APP(V717F+/-) Apoe(-/-) TG mice at any of the time points examined. The absence of apolipoprotein E protein (apoE) dramatically reduced the amount of both Aβ1-40 and Aβ1-42 immunoreactive deposits as well as the resulting astrogliosis and microgliosis normally observed in APP(V717F) TG mice. ApoE immunoreactivity was detected in a subset of Aβ immunoreactive deposits and in virtually all thioflavine-S-fluorescent amyloid deposits. Because the absence of apoE alters neither the transcription or translation of the APP(V717F) transgene nor its processing to Aβ peptide(s), we postulate that apoE promotes both the deposition and fibrillization of Aβ, ultimately affecting clearance of protease-resistant Aβ/apoE aggregates. ApoE appears to play an essential role in amyloid deposition in brain, one of the neuropathological hallmarks of Alzheimer's disease.",
author = "Bales, {Kelly R.} and Tatyana Verina and Cummins, {David J.} and Yansheng Du and Dodel, {Richard C.} and Josep Saura and Fishman, {Cindy E.} and Delong, {Cynthia A.} and Pedro Piccardo and Valerie Petegnief and Bernardino Ghetti and Paul, {Steven M.}",
year = "1999",
month = "12",
day = "21",
doi = "10.1073/pnas.96.26.15233",
language = "English",
volume = "96",
pages = "15233--15238",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "26",

}

TY - JOUR

T1 - Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease

AU - Bales, Kelly R.

AU - Verina, Tatyana

AU - Cummins, David J.

AU - Du, Yansheng

AU - Dodel, Richard C.

AU - Saura, Josep

AU - Fishman, Cindy E.

AU - Delong, Cynthia A.

AU - Piccardo, Pedro

AU - Petegnief, Valerie

AU - Ghetti, Bernardino

AU - Paul, Steven M.

PY - 1999/12/21

Y1 - 1999/12/21

N2 - We quantified the amount of amyloid β-peptide (Aβ) immunoreactivity as well as amyloid deposits in a large cohort of transgenic mice overexpressing the V717F human amyloid precursor protein (APP(V717F+/-) TG mice) with no, one, or two mouse apolipoprotein E (Apoe) alleles at various ages. Remarkably, no amyloid deposits were found in any brain region of APP(V717F+/-) Apoe(-/-) TG mice as old as 22 mo of age, whereas age-matched APP(V717F+/-) Apoe(+/-) and Apoe(+/+) TG mice display abundant amyloid deposition. The amount of Aβ immunoreactivity in the hippocampus was also markedly reduced in an Apoe gene dose-dependent manner (Apoe(+/+) > Apoe(+/-) >> Apoe(-/-)), and no Aβ immunoreactivity was detected in the cerebral cortex of APP(V717F+/-) Apoe(-/-) TG mice at any of the time points examined. The absence of apolipoprotein E protein (apoE) dramatically reduced the amount of both Aβ1-40 and Aβ1-42 immunoreactive deposits as well as the resulting astrogliosis and microgliosis normally observed in APP(V717F) TG mice. ApoE immunoreactivity was detected in a subset of Aβ immunoreactive deposits and in virtually all thioflavine-S-fluorescent amyloid deposits. Because the absence of apoE alters neither the transcription or translation of the APP(V717F) transgene nor its processing to Aβ peptide(s), we postulate that apoE promotes both the deposition and fibrillization of Aβ, ultimately affecting clearance of protease-resistant Aβ/apoE aggregates. ApoE appears to play an essential role in amyloid deposition in brain, one of the neuropathological hallmarks of Alzheimer's disease.

AB - We quantified the amount of amyloid β-peptide (Aβ) immunoreactivity as well as amyloid deposits in a large cohort of transgenic mice overexpressing the V717F human amyloid precursor protein (APP(V717F+/-) TG mice) with no, one, or two mouse apolipoprotein E (Apoe) alleles at various ages. Remarkably, no amyloid deposits were found in any brain region of APP(V717F+/-) Apoe(-/-) TG mice as old as 22 mo of age, whereas age-matched APP(V717F+/-) Apoe(+/-) and Apoe(+/+) TG mice display abundant amyloid deposition. The amount of Aβ immunoreactivity in the hippocampus was also markedly reduced in an Apoe gene dose-dependent manner (Apoe(+/+) > Apoe(+/-) >> Apoe(-/-)), and no Aβ immunoreactivity was detected in the cerebral cortex of APP(V717F+/-) Apoe(-/-) TG mice at any of the time points examined. The absence of apolipoprotein E protein (apoE) dramatically reduced the amount of both Aβ1-40 and Aβ1-42 immunoreactive deposits as well as the resulting astrogliosis and microgliosis normally observed in APP(V717F) TG mice. ApoE immunoreactivity was detected in a subset of Aβ immunoreactive deposits and in virtually all thioflavine-S-fluorescent amyloid deposits. Because the absence of apoE alters neither the transcription or translation of the APP(V717F) transgene nor its processing to Aβ peptide(s), we postulate that apoE promotes both the deposition and fibrillization of Aβ, ultimately affecting clearance of protease-resistant Aβ/apoE aggregates. ApoE appears to play an essential role in amyloid deposition in brain, one of the neuropathological hallmarks of Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=0033593027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033593027&partnerID=8YFLogxK

U2 - 10.1073/pnas.96.26.15233

DO - 10.1073/pnas.96.26.15233

M3 - Article

C2 - 10611368

AN - SCOPUS:0033593027

VL - 96

SP - 15233

EP - 15238

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 26

ER -